P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 18-18
10.1097/01.hs9.0000829624.40467.0d